



## Notice of Annual General Meeting and Grant of ASX Waiver

**Melbourne, Australia – 25 October 2019:** Medical device company dorsaVi Ltd (ASX: DVL) (**'Company'**) has today released its Notice of Annual General Meeting (**'Notice'**) in respect of the financial year ended 30 June 2019 to be held at the Melbourne office of Pitcher Partners at Level 13, 664 Collins Street, Docklands, Victoria, 3008 on Thursday, 28 November 2019 at 10:00 am (AEDT).

The Company is pleased to advise that ASX Limited (**'ASX'**) has granted the Company a waiver from ASX Listing Rules 10.13.3 and 10.13.5 to the extent necessary to permit the Company's shareholders to approve the issue of options to Mr Greg Tweedly, Mr Ashraf Attia, Ms Caroline Elliott and Mr Michael Panaccio (or their respective nominees) (**'Directors'**) in lieu of their remuneration (**'Remuneration Options'**) on the terms contained in the explanatory notes accompanying the Notice.

Where an entity seeks approval from its shareholders to issue securities to its directors, or other related parties, for the purposes of ASX Listing Rule 10.11:

- ASX Listing Rule 10.13.3 requires the date by which the entity proposes to issue those securities to be disclosed in the notice of meeting, and in particular requires that the date be no later than 1 month following the date of the meeting; and
- ASX Listing Rule 10.13.5 requires the notice of meeting to state the issue price and terms of issue of securities that are intended to be issued.

The waiver was required because a portion of the Remuneration Options will be issued later than one month after the date of the Annual General Meeting (**'AGM'**), and the issue price of those Remuneration Options is not yet able to be determined. The waiver of Listing Rules 10.13.3 and 10.13.5 is only to the extent that:

- the Notice is not required to state that the Remuneration Options will be issued within 1 month of the AGM; and
- the Notice does not have to specifically state the issue price of the Remuneration Options.

Each waiver is subject to the following conditions.

1. The Remuneration Options are issued no later than 5 business days after the end of the relevant quarter.
2. The Remuneration Options are issued no later than 7 October 2020.
3. The Notice contains the full terms and conditions of the Remuneration Options.
4. The Company's annual report for any period during which the Remuneration Options are issued to the Directors, discloses details of the number of Remuneration Options that were issued to them, including the percentage of the Company's issued capital represented by those Remuneration Options.

5. The Notice includes a worked example of the dilution that will occur to existing shareholders of the Company as a result of the issue of the Remuneration Options.
6. The terms of the waiver are released to the market at the same time the Notice is released to the market by way of a separate announcement.

For more details regarding the Remuneration Options please see the explanatory notes which accompany the Notice released on the Company's ASX market announcements platform today.

– ENDS –

### ***About dorsaVi***

dorsaVi (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions - ViMove, ViMove2 and Professional Suite – which provide objective assessment, monitoring outside the clinic and immediate biofeedback. dorsaVi is currently used by medical and physiotherapy practices globally.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used in the US by the National Basketball Association (NBA), the Major Soccer League (MLS) and the National Football League (NFL), by the AFL and NRL clubs and by Barclays Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally.
- **Occupational Health and Safety (OHS):** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), and BHP Billiton.

Further information is available at [www.dorsavi.com](http://www.dorsavi.com).